32 related articles for article (PubMed ID: 24787231)
21. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
Faulkner RD; Craddock C; Byrne JL; Mahendra P; Haynes AP; Prentice HG; Potter M; Pagliuca A; Ho A; Devereux S; McQuaker G; Mufti G; Yin JL; Russell NH
Blood; 2004 Jan; 103(2):428-34. PubMed ID: 12969983
[TBL] [Abstract][Full Text] [Related]
22. Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.
Noriega V; Kaur H; Devereux S; Byrne J; Marcus R; Haynes A; Yallop D; McMillan A; Ingram W; Khan A; Kenyon M; Potter V; Russell N; Mufti GJ; Pagliuca A
Leuk Res; 2014 Jul; 38(7):737-43. PubMed ID: 24787231
[TBL] [Abstract][Full Text] [Related]
23. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
[TBL] [Abstract][Full Text] [Related]
24. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
25. Changing role of stem cell transplantation in follicular lymphoma.
Laport GG
Hematology Am Soc Hematol Educ Program; 2012; 2012():417-25. PubMed ID: 23233613
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic stem cell transplantation for follicular lymphoma: optimal timing and indication.
Kim SW
J Clin Exp Hematop; 2014; 54(1):39-47. PubMed ID: 24942945
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.
Epperla N; Hamadani M
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):277-284. PubMed ID: 28633038
[TBL] [Abstract][Full Text] [Related]
28.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
